ClinicalTrials.gg
CompletedNCT06824948Updated Feb 13, 2025

Evaluate the Safety, Tolerance, and Pharmacokinetic Profiles of Timolol Maleate Gel

A Phase 1 interventional study of Timolol Maleate Gel and Placebo in Healthy Subjects, sponsored by Auson Pharmaceuticals Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Auson Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 3 months after the study started (first participant enrolled Oct 2018, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to to evaluate the safety, tolerance, and pharmacokinetic profiles of Timolol Maleate Gel in healthy Chinese adult subjects. The main questions aim to answer are:

  • The pharmacokinetic endpoints: Single dose:Tmax, Cmax, etc. Multiple doses:AUC0-t, AUC0-inf, λz, t1/2, etc.
  • The safety and tolerance endpoints: Physical examination, vital signs, 12-lead ECG, laboratory tests (hematology, blood biochemistry and urinalysis), adverse events, local tolerance.

Researchers will compare TM gel to a placebo (a look-alike substance that contains no drug) to see if TM gel works to treat IH.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Auson Pharmaceuticals Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male or female subjects aged 18-55 years (including the cut point, subject to the time of signing the ICF);
  2. Subjects with the (BMI) of 19-26 kg/m2 (including the cut point), where the body weight should be ≥ 50 kg for male subjects and ≥ 45 kg for female subjects;
  3. Subjects who have no pregnancy plan, voluntarily adopt effective birth controls, and have no sperm donation or egg donation plan during the study until 3 months after the last dose. For specific birth controls, see Appendix 1: , Definition of Female Subjects of Childbearing Age, and Contraception Requirements;
  4. Subjects fully understand the study objective, nature, methods and possible adverse reactions, voluntarily become subjects, and sign the ICFs;
  5. Subjects who have no skin damage or scar or skin disease at the administration site; Subjects who can complete the trial as required in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who are allergic to timolol maleate and similar drugs;
  2. Subjects who have any difficulty in venous blood collection;
  3. Subjects who have cardiogenic shock, Grade I or Grade III atrioventricular block, cardiac failure, sinus bradycardia, hypotension, and CS as assessed by the study physician;
  4. Subjects who have bronchial asthma, airway sensitive disease, ventilation difficult or other pulmonary disorders;
  5. Subjects who have had a history of drug abuse in the past five years or used drugs within the 3 months before the study; or subjects who are positive in the drug abuse screening test in the screening phase;
  6. Subjects who have smoked more than 5 cigarettes a day within the 3 months before screening;
  7. Subjects who have consumed more than 14 units of alcohol (1 unit of alcohol = 360 mL beer or 45 mL 40% spirits or 150 mL wine) weekly within 6 months before the screening or have taken alcohol-containing products 48 h pre-dose, or were or positive in the alcohol breath test in the screening phase and/or the baseline phase;
  8. Subjects who have used any drug that induces or inhibits liver metabolic enzymes within 28 days pre-dose in the study;
  9. Subjects who have used any Rx, OTC or Chinese herbal medicine within 14 days pre-dose in the study;
  10. Subjects who have took food or drink (such as grapefruit) containing enzymes that can induce or inhibit liver metabolism within 7 days pre-dose in the study;
  11. Subjects who have ingested any food or drink containing caffeine or xanthine (e.g., coffee, tea, chocolate) during the period at 48 ho pre-dose to completion of the last PK blood sampling;
  12. Subjects who have diseases or factors with clinical abnormalities, including but not limited to neurological, cardiovascular, blood, liver, kidney, gastrointestinal, respiratory, metabolic, endocrine, immune, skeletal system diseases or other factors;
  13. Results of the vital signs assessment, physical examinations, laboratory test, 12-lead and chest radiograph showed CS;
  14. Subjects who are (HIV) antibody positive, surface antigen positive, virus antibody positive, or syphilis antibody positive;
  15. Female subjects who are positive for pregnancy test in the screening phase or the baseline phase or who are breastfeeding;
  16. Subjects who have had a major disease or major surgical procedure within 4 weeks prior to dosing, or was expected to require major surgery during the study;
  17. Subjects who have participated in other clinical drug trials within 3 months pre-dose in the study;
  18. Subjects who have donated blood or blood loss > 400 mL within 3 months before screening; Any other circumstances that may affect the subjects in providing ICFs or following the study protocol, or participation in the study may affect the study results or the subjects' own safety as assessed by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Group 2-0.5%TM

    Participants will be randomized to receive 0.5%TM or matching placebo 2 times a day.

    Drug: Timolol Maleate Gel · Drug: Placebo

  • Experimental
    Group 3-0.5%TM

    Participants will be randomized to receive 0.5%TM or matching placebo 3 times a day.

    Drug: Timolol Maleate Gel · Drug: Placebo

  • Experimental
    Group 1-0.5%TM

    Participants will be randomized to receive 0.5%TM or matching placebo 1 time a day.

    Drug: Timolol Maleate Gel · Drug: Placebo

Interventions

  • A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel one time a day during Day 3-Day 12.

  • DrugPlacebo

    A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo one time a day during Day 3-Day 12.

  • A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel 2 times a day during Day 3-Day 12.

  • DrugPlacebo

    A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo 2 times a day during Day 3-Day 12.

  • A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel 3 times a day during Day 3-Day 12.

  • DrugPlacebo

    A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo 3 times a day during Day 3-Day 12.

06

What researchers measure

Primary outcomes

  1. Local tolerance

    Local tolerance will be evaluated by an investigator or designated evaluator (e.g., dermatologist) using the blinding method.The intensity (e.g., No evidence of irritation;Minimal erythema that is barely perceptible;Definite erythema that is readily visible and minimal edema or minimal papular response;Erythema and papules, et al) of the skin response is assessed on a 8 point scale.Other response score is assessed from "A" to "H".

    Time frame: 13 Days

  2. Adverse events

    Frequency, severity and relatedness of adverse events

    Time frame: Throughout study completion, an average 13 days

  3. Vital signs (blood pressure)

    Number of participants with clinically significant changes in vital signs (blood pressure)

    Time frame: the screening phase, Day -1, Day 1, 3, 6, 9, 12, and Day 13.

  4. Vital signs (temperature)

    Number of participants with clinically significant changes in vital signs (temperature)

    Time frame: the screening phase, Day -1, Day 1, 3, 6, 9, 12, and Day 13.

  5. Vital signs (pulse rate)

    Number of participants with clinically significant changes in vital signs (pulse rate)

    Time frame: the screening phase, Day -1, Day 1, 3, 6, 9, 12, and Day 13.

  6. Laboratory tests

    Number of participants with clinical laboratory abnormalities (including hematology, blood biochemistry and urinalysis).

    Time frame: the screening phase, the baseline phase, and on Days 6 and 13.

  7. Physical examinations

    Number of participants with clinically significant changes in physical examinations.

    Time frame: the screening phase, baseline phase and on Day 13

  8. 12-lead ECG

    Number of participants with clinically significant changes in 12-lead ECG.

    Time frame: the screening phase, baseline phase, Day 1, 3, 6, 9, 12, and Day 13.

Secondary outcomes

  1. Tmax

    The pharmacokinetics of single and multiple dose levels in participants will include peak time.

    Time frame: Day1 to Day13

  2. Cmax

    The pharmacokinetics of single and multiple dose levels in participants will include peak concentration.

    Time frame: Day1 to Day13

  3. AUC0-t

    The pharmacokinetics of single and multiple dose levels in participants will include area under drug concentration-time curve.

    Time frame: Day1 to Day13

  4. AUC0-inf

    area under drug concentration-time curve (AUC0-t) from 0 to t for the last accurately measurable concentration, area under drug concentration-time curve from 0 to infinity

    Time frame: Day1 to Day13

  5. λz

    The pharmacokinetics of single and multiple dose levels in participants will include elimination rate constant.

    Time frame: Day1 to Day13

  6. t1/2

    The pharmacokinetics of single and multiple dose levels in participants will include elimination half-life.

    Time frame: Day1 to Day13

  7. %AUCex

    The pharmacokinetics of single and multiple dose levels in participants will include AUC extrapolation percentage.

    Time frame: Day1 to Day13

07

Study locations

1 site
  • Shanghai Xuhui District Central Hospital
    Shanghai, Shanghai 200031, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Dec 2018, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Feb 13, 2025
StartActual
Oct 12, 2018
Primary completionActual
Dec 12, 2018
CompletionActual
Dec 12, 2018
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06824948
Lead sponsor
Auson Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Feb 13, 2025
Start date
Oct 12, 2018
Primary completion
Dec 12, 2018
Completion
Dec 12, 2018
Last update
Feb 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Timolol

Start the discussion